Rapid developments in the field of CAR T cells offer important new opportunities
while at the same time increasing numbers of patients pose major challenges. This
review is summarizing on the one hand the state of the art in CAR T cell trials with a
unique perspective on the role that Europe is playing. On the other hand, an overview
of reproducible processing techniques is presented, from manual or semi-automated
up to fully automated manufacturing of clinical-grade CAR T cells. Besides regulatory
requirements, an outlook is given in the direction of digitally controlled automated
manufacturing in order to lower cost and complexity and to address CAR T cell products
for a greater number of patients and a variety of malignant diseases.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84322 |
| Date | 27 March 2023 |
| Creators | Vucinic, Vladan, Quaiser, Andrea, Lückemeier, Philipp, Fricke, Stephan, Platzbecker, Uwe, Koehl, Ulrike |
| Publisher | Frontiers Research Foundation |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 2296-858X, 713401 |
Page generated in 0.0029 seconds